BioTrinity 2016

BioTrinity has grown in terms of numbers and quality of attendees year on year. To see what happened and who attended previous BioTrinity conferences take a look at our archive:

Participants 2016

Red = Global Pharma/MedTech corporates
Green = Investors and financial service firms
Blue = Exhibitors

11 Health and Technologies Ltd
2BIND GMBH (Germany)
3P Biopharmaceuticals (Spain)
A J Gallagher
A. Menarini I.F.R. (Italy)
AbbVie (USA)
Abbvie Ventures (United States)
ABF Pharmaceutical Services (Austria)
Abgentis Ltd
Abingworth LLP
ABPI
Abzena plc
Acarix A/S (Denmark)
Acrux (Australia)
Action on Hearing Loss
Advantage Austria
Advent Life Sciences
Aetas Global Markets (Hong Kong)
Air Liquide plc
Air Products plc
Akesios Associates
Akinion Pharmaceutical AB (Sweden)
Alacrita
Albany Molecular Research Inc. (AMRI)
Albion Ventures LLP
Albumedix (Denmark)
Alderley Analytical
Alderley Park
Alderley Park Ventures
Alesi Surgical Limited
Alfacyte Ltd
Almac
Amadeus Capital Partners
Amal Therapeutics (Switzerland)
Amgen
AMRC
Angel Capital Group
Antikor Biopharma Ltd
apceth GmbH & Co. KG (Germany)
APEPTICO (Austria)
Apex Healthcare Consulting Ltd
APIM Therapeutics (Norway)
Apitope
Aptuit
Aptus Clinical Limited
Arcus Altor Ltd
Ario Pharma
Arthritis Research UK
Arthur J. Gallagher
Arthurian Life Sciences
Asajes Medical (Japan)
Association of the British Pharmaceutical Industry
Asterias Biotherapeutics (United States)
Aston University - Business Partnership Unit
AstraZeneca
Atopix Therapeutics Ltd
Aurealis Pharma (Finland)
Aurelia Bioscience
Auspherix Ltd
Austrian Trade Commission
Autolus Ltd
Autonomous University of Barcelona (Spain)
Avego Healthcare Capital (United States)
Avexxin AS (Norway)
Babraham Institute Enterprise Ltd
Bard Pharmaceuticals (Napp Pharmaceutical Group)
Baxalta Ventures (United States)
Bayer Pharma AG (Germany)
BC Platforms (Switzerland)
BeamLine Diagnostics
Belgian Embassy
BerGenBio (Norway)
BIA
BioCity Group Ltd
Biofarma Research Group, University of Santiago de Compostela (Spain)
BioFocus DPI Ltd.
BioGateway
BioGeneration Ventures (The Netherlands)
BioMarker Strategies, LLC (United States)
BioMotiv, LLC (United States)
Biomunex Pharmaceuticals (France)
Bionow
Biopharm Insight (Mergermarket)
Biopharma-Reporter.com (France)
BiOrion Technologies BV (Netherlands)
Bioshai (Israel)
Biotech Personnel
Biotech Therapeutics (France)
Biotechgate
Biotecnol Limited
Biotrial International
Black Swan Analysis
Bloomberg Intelligence
Bloomberg News
Blueberry Therapeutics
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb (United States)
Bristows
British Heart Foundation
Brown Rudnick LLP
BTG plc
Business Upper Austria (Austria)
C4X Discovery
Cambridge Enterprise
Cambridge Enterprise Seed Funds
Cambridge Healthcare & Biotech
Cambridge Innovation Capital plc
Canaccord Genuity
Cancer Research UK
Capricorn Venture Partners (Belgium)
Catapult Ventures
Cell Medica Ltd
Cellestia Biotech (Switzerland)
Cellnovo Group SA (France)
Cellnovo Ltd
Cello Health Consulting
CFT Ltd
Champions Oncology, Inc. (Germany)
Charles River
ChemPartner Europe (Denmark)
Chiltern Oncology
Chronos Therapeutics
Citigate Dewe Rogerson
Cleveland
Cleveland Patents and Trade Marks
Clindox Ltd (Ireland)
Clinica Medtech Intelligence
Clinical Biomanufacturing Facility, University of Oxford
Clinical Network Services (UK) Ltd
Clubb Capital Ltd
CN Bio Innovations
Cobra Biologics
Coller IP
Combebelle Life
Communications Strategy Group Inc. (United States)
Confluence Tax LLP
Consulting Services Solioz (Switzerland)
Coulter Partners
Covance
CPI (Centre for Process Innovation)
CPL Scientific
Credos Consulting Limited
Crescendo Biologics Ltd
Crossject (France)
CRUK
Crystallics (Netherlands)
CTS Inc. (United States)
Curileum Discovery Ltd
Current Partnering
Cypralis Ltd
Cytovation AS (Norway)
Cytox Ltd
DanMedical
DanMedical Ltd
Datamonitor Healthcare & SCRIP Intelligence
DDF Ventures bv (Netherlands)
Debiopharm International SA (Switzerland)
Decision Resources Group
Destiny Pharma Ltd
Diamond BioPharm
Diligent Business Consulting Ltd
Discovery Park
DJS Antibodies
Domainex Limited
Dora Wirth (Languages) Ltd.
Draper Esprit
Drooms GmbH (Germany)
Drug Discovery Today
Duke Street
Dynasty Bio/The Dynasty Fund
e-Therapeutics Plc
EA Pharma Co., Ltd (Japan)
EBD Group
Edinburgh Molecular Imaging
Edmond de Rothschild Investment Partners (France)
Elasmogen Ltd
Enterprise Europe Network
Envigo
EP Vantage
Epidarex Capital
Epiphany Capital
Eucodis Bioscience GmbH (Austria)
Eudendron Srl (Italy)
Eurasante
Eurofins Bioanalytical Services
Euromedica
EUSA Pharma
Evernow Publishing Ltd (Belgium)
Evolution Life Science Partners (United States)
Evotec (UK) Ltd
Exochrome Biosceinces Limited
EY
F-Prime Capital
F-star Biotechnology Ltd
FibroTx LLC (Estonia)
FieldFisher
FierceBiotech (USA)
Finance Wales
Financial Times
Fisher Scientific
Flanders Investment and Trade
FlandersBIO (Belgium)
FNB Medical
Forbion Capital Partners (Netherlands)
FordPharma (United States)
Fountain Healthcare Partners (Ireland)
Fraunhofer Institute for Cell Therapy and Immunology (Germany)
FreeMind Group (United States)
FTI Consulting
FutuRx Ltd (Israel)
GalbraithWight Europe (Italy)
GeneaMed Ltd. (Poland)
GeneFirst
Genomics England
Genomics plc
George James Ltd
Gilde Healthcare (Netherlands)
GLE Group
GLG (United States)
Glide Technologies
Global Care Initiative (France)
GlobalData PLC
Globe Life Sciences
Greater London Enterprise
Greaves Brewster LLP
GreenBone Ortho srl (Italy)
Grenoble Alpe University (France)
Hadean Ventures (Norway)
Hammersmith Medicines Research
Harbert European Growth Capital
Harwell Oxford
Hays Life Science
HBM Partners (Switzerland)
HC Pharma Consultancy Ltd
Healx
Heptares Therapeutics Ltd
HGF Limited, Intellectual Property Specialists
High-Tech Gründerfonds Management GmbH (Germany)
HistologiX
Honeywell
Horton International
Hygieia Inc
Hyperion Corporate Development
Hypo-Stream Ltd
i3a Technologies (Austria)
Icex España Exportacion e Inversiones (Spain)
ICON Clinical Research (Ireland)
ICT Innovation in Clinical Trials (Austria)
IDF INNOV (France)
Ignite Capital Partners
Illetrop Limited
Illingworth Research
IM Therapeutics (United States)
Imanova Limited
Imevax GmbH
Immatics Biotechnologies GmbH (Germany)
IMMT Ltd. (Slovenia)
Imperial Innovations
Inflamalps SA (Switzerland)
Informa (Citeline)
Innovate UK
Innovation Forum
InnovationDB
INOVOTION (France)
Insights in Life Sciences (ILS)
Instinctif Partners
Institut de Recherche Pierre Fabre (France)
InSymbiosis (Canada)
International Labmate
Inventages
Investor - Alex Griffiths
IP Asset Partnership
IP Group
IP Pragmatics Ltd
IPF (Luxembourg)
IPI
Ipsen Bioinnovation Ltd
Ipsen Biopharm Limited
Ipsen Pharma (France)
Irving Levin Associates
Isansys Lifecare
Isis Innovation
Isle of Man Government (Isle of Man)
J A Kemp
J&J Innovation London
J&J Innovation – JJDC
J&P Medical Research Ltd. (Austria)
James Cowper Kreston
JB Equity
Joint Polish Investment Fund (Poland)
Jon Rees Associates
JP Morgan Asset Management
JT Pharma (United States)
Juno Therapeutics (USA)
Karus Therapeutics
Kathryn Simpson Consulting
Kevin Pritchard Consulting
Key Organics
King's College London
Kinnov Therapeutics (France)
Knowledge Transfer Network
Kurma Partners
KWS BioTest
La Jolla Pharmaceutical Company (United States)
Labiotech.eu (Germany)
Lancaster China Catalyst Programme
Lantern Pharma (United States)
Leads To Development (France)
Levrett plc
Life Science Austria Vienna - LISAvienna (Austria)
Life Science Nation
Life Sciences Hub Wales
Liftstream
Ligand Pharmaceuticals (United States)
Lightstone Ventures (United States)
Lilly
Loki Steer (Ireland)
London Business Angels
Lonestar Strategies
Longwall Ventures
Lonza (Switzerland)
Loxbridge Research Capital LLP
LSP Life Sciences Partners (Netherlands)
Ludger Ltd
Lyonbiopole (France)
Mabvax Therapeutics (United States)
Magle Chemoswed (Sweden)
Management Learning & Coaching Ltd (ML&C)
Manchester Science Partnerships
Manentia Ltd
Manentia Ltd
Mann Bioinvest Limited
Mapmyhealth
Marks & Clerk LLP
Master Investor Ltd.
Mathys & Squire LLP
Mathys & Squire LLP
MD Anderson Cancer Center (United States)
MedCity
MEDIAN Technologies (France)
Medicines & Healthcare products Regulatory Agency (MHRA)
Medicxi Ventures
Mediqventures Ltd. (Isle of Man)
MedNous
Medtrack (United States)
MedX Health Corporation
MEPC Ltd
Mercia Technologies
Merck (France)
Mereo BioPharma Group Limited
Mergermarket Group
Mettler Toledo (Uganda)
MGB Biopharma Ltd
MHRA
MIDAS, Manchester's Inward Investment Agency
Midven
MiNA Therapeutics
MISSION Therapeutics
Mitsubishi Tanabe Pharma Europe
Mitsui & Co. Global Investment, Inc. (Japan)
Momentum Bioscience
MS Ventures (Netherlands)
MSD
Mucosis (United States)
MVM Life Science Partners LLP
MyoPowers Medical Technologies (France)
N4 Pharma limited
N8 Research Partnership
NALIA Systems Limited
Nanobiotix (France)
Nanomerics Ltd
Nature Biotechnology
Nature Publishing Group
NBGI Private Equity Limited
NeoMed (Switzerland)
Neovacs (France)
NeRRe Therapeutics Ltd
NetScientific
Neuro-Bio Ltd
Neurocentrx
New Wave Ventures
Nexstim (Finland)
Nexvet Biopharma plc (Australia)
NHSA Ltd
NIHR Clinical Research Network
NIHR Moorfields Biomedical Research Centre
NIMGenetics (Spain)
Norgine Ventures
Northern Health Science Alliance
Northern Powerhouse
Nova Language Services Ltd.
Novartis Venture Fund (Switzerland)
Novasecta
Novo A/S (Denmark)
NPSC
Numis Securities
O2h Ventures Limited
Oberland Capital (Sweden)
OBN (UK) Ltd
OBS Medical
Odgers Berndtson
Omnes Capital (France)
Oncascan
OncoQR ML (Austria)
OncoTherics Ltd
Opsona Therapeutics Ltd. (Ireland)
ORA INC (United States)
ORAVision Ventures (United States)
Orbit Discovery Ltd
Orla Protein Technologies
OrthoSera GmbH (Austria)
OrthoSera GmbH (Austria)
Oryzon Genomics (Spain)
Osborne Clarke LLP
Oxford Academic Health Science Network (AHSN)
Oxford Academic Health Science Network (AHSN), Medicines Optimisation Clinical Network
Oxford BioElectronics
Oxford BioTherapeutics
Oxford Brookes University
Oxford Cancer Biomarkers
Oxford Genetics
Oxford MESTAR Ltd
Oxford Molecular Diagnostics Centre
Oxford Science Park
Oxford Sciences Innovation
Oxford Technology
Oxford University
Oxford University Hospitals NHS Trust and the University of Oxford
Oxfordshire Local Enterprise Partnership (OxLEP)
OxSonics Limited
Panacea Innovation
Panacea Innovation
Panakès Partners (Italy)
Parkinson's UK
Patheon
Patheon (United States)
PCI Biotech AS (Norway)
PCI Clinical Services
Pcovery ApS (Denmark)
PDL BioPharma, Inc. (United States)
Peak Proteins Ltd.
Peakdale Molecular
Penningtons Manches
Penningtons Manches LLP
Peptinnovate Limited
Perceptive Bioscience Investment
Perficient
Pfizer
Pharm-Olam International
Pharma Publications
Pharmalicensing
pharmaphorum
Pharmaterials Ltd
PharmaVentures
Phision Therapeutics / University College Dublin (Ireland)
Photo Dynamic Therapy LLC (Austria)
Physiomics Plc
Pierre Fabre (France)
Pierre Fabre Fund for Innovation (France)
Pierre Fabre Medicament (France)
Pierre Fabre Research Institute (France)
Pinsent Masons
PIQUR Therapeutics AG (Switzerland)
Piramal Pharma Inc (Iceland)
Piramal Pharma Solutions (India)
Platomics GmbH (Austria)
Polar Capital Partners
PolTREG Ltd
PRAGMA Therapeutics (France)
Precision Medicine Catapult
PRECLIN Biosystems AG (Switzerland)
PrEP Biopharm (United States)
Private Investor
ProAxsis Ltd
Proximagen Ltd
PsiOxus Therapeutics Ltd
Public Health England
QRC Consultants Ltd
Quanta Fluid Solutions
Quay Pharma
Queen Mary Innovation
Queen's University Belfast
Quethera Ltd
Quintiles
Quotient Clinical
Qures Healthcare
R&D Focus Drug News
R-Outcomes (and Abies Ltd)
Rainbow Seed Fund
Re-Pharm
Re-Vana Ltd
Redoxis (Sweden)
Redx Pharma
Remiges Ventures (United States)
Renfrew Group International
Respivert Ltd
Results Healthcare
Rex Bionics plc
Richmond Pharmacology Ltd
Ridgefield Consulting Ltd
Ripptide Pharma Ltd.
Rosetta Capital Ltd
Roundcape Ltd
Royal Holloway, University of London
RR Donnelley
RSA
Ryan-Kay
Ryboquin Company Ltd
Safeguard Biosystems
Samedan Ltd
Samsung BioLogics (Korea, South)
Samsung Ventures
Sanofi (France)
Santen, Inc. (United States)
Sareum
SATT Grand Est (France)
SCI
Sciad Communications Ltd
Scottish Enterprise
Scrip Intelligence
Selcia Ltd
Selvita Ltd
SEP (Scottish Equity Partners)
Seroba Life Sciences (Ireland)
Seventure Partners (France)
Shikubeisho Partners (France)
Shin Poong Pharma
Silence Therapeutics
Silicon Valley Bank
Sitatunga Ltd
SIX Swiss Exchange (Switzerland)
SkyLab Bio
Sofinnova Partners (France)
Somanautix
Spark Impact
Springer Nature
SR One
SRG
Stevenage Bioscience Catalyst
Stifel
Stratified Medicine Scotland
STRI-bBHC (South Korea)
Structural Genomics Consortium, University of Oxford
Summit Therapeutics
Sunstone Capital (Denmark)
SV Life Sciences
Sygnature Discovery Limited
SynbiCITE
Syncona Partners
SyndicateRoom
SyndicateRoom
Syne qua non
Synpromics Ltd
SYNthesis med chem
TagCyx Biotechnologies (Japan)
Takeda Pharmaceutical Company Limited
Takeda Pharmaceuticals International, Inc. (United States)
Takeda Ventures, Inc. (United States)
Tawhai Ltd
Telocyte
Teva Pharmaceutical Industries, Ltd. (Netherlands)
Tharsus
The BioHub Birmingham
The Corporate Development Company (Switzerland)
The Fulford Group
The Institute of Cancer Research
The Pharma Letter
The Royal Veterinary College
Theradex Europe
Theraldia Consulting Ltd
Thermo Fisher Scientific
Thromboserin
Tissue Regenix
Tissue Solutions Ltd
Torreya Partners
Touchlight Genetics Ltd
TranScrip
Transcriptogen Ltd
Trianni, Inc. (United States)
Tusk Therapeutics
TVM Life Science Management (Germany)
TYG oncology
UCB Biopharma sprl (Belgium)
UCL Business PLC
UK Government
UK Government, Office of Life Sciences
UKTI
UKTI Life Sceinces Organisation
Umecrine Cognition AB (Sweden)
Unguis Medical
University College London (UCL)
University of Birmingham
University of Dundee
University of Gdansk (Poland)
University of Leicester
University of Oxford
University of Reading
University of St Andrews
University of Tartu (Estonia)
UNSW Innovations (Australia)
V-Bio Ventures (Belgium)
VCLS
Ventac Partners (Spain)
Venture Valuation (Switzerland)
Vermilion Life Sciences
Vernalis
VHsquared Ltd
Vifor Pharma Ltd. (Switzerland)
VirdisGroup Ltd.
Virttu Biologics Ltd
Visium Asset Management
Visusnano
W Life Sciences (Switzerland)
Wall Street Journal
Warwick Ventures Ltd
Wellcome Trust
Wellington Partners (Germany)
Wessex Academic Health Science Network
Wessex Life Science Cluster
West Sussex County Council
WG Partners LLP
White October
Wickham Laboratories Limited
Wiltshire Council
Woodford Investment Management
World Courier UK Ltd
Worldwide Clinical Trials
Wren Capital
Wuesthoff & Wuesthoff (Germany)
WuXi AppTec
Xplico A/S (Denmark)
Yorkville Advisors Global (United States)
Ysios Capital (Spain)
Zealand Pharma A/S (Denmark)
Zurich University of Applied Sciences (Switzerland)

Investors and Financial Services Firms 2016

BioTrinity 2016 was yet another bumper year for attracting investment delegates from about 115 firms from 12 countries. Many firms sent multiple delegates. We actively monitored the quality of investors permitted to participate, to ensure the ongoing quality of representation.  In addition a growing number of lead Angels specialising in life sciences investing attended, but for privacy they are not necessarily listed below.

Abbvie Ventures (United States)
Abingworth LLP
Advent Life Sciences
Aetas Global Markets (Hong Kong)
Akesios Associates
Albion Ventures LLP
Alderley Park Ventures
Amadeus Capital Partners
Angel Capital Group
Arthurian Life Sciences
Avego Healthcare Capital (United States)
Baxalta Ventures (United States)
BioGeneration Ventures (The Netherlands)
BioMotiv, LLC (United States)
Boehringer Ingelheim GmbH (Germany)
Cambridge Enterprise Seed Funds
Cambridge Innovation Capital plc
Canaccord Genuity
Capricorn Venture Partners (Belgium)
Catapult Ventures Clubb Capital Ltd
Draper Esprit
Duke Street
Dynasty Bio/The Dynasty Fund
Edmond de Rothschild Investment Partners (France)
Epidarex Capital
Epiphany Capital
Evolution Life Science Partners (United States)
F-Prime Capital
Finance Wales
Forbion Capital Partners (Netherlands)
FordPharma (United States)
Fountain Healthcare Partners (Ireland)
Gilde Healthcare (Netherlands)
GLE Group
Hadean Ventures (Norway)
Harbert European Growth Capital
HBM Partners (Switzerland)
High-Tech Gründerfonds Management GmbH (Germany)
Hygieia Inc
Ignite Capital Partners
Imperial Innovations
Inventages
IP Group
IPF (Luxembourg)
J&J Innovation – JJDC
JB Equity
Joint Polish Investment Fund (Poland)
JP Morgan Asset Management
Kurma Partners
Lightstone Ventures (United States)
London Business Angels
Longwall Ventures
Loxbridge Research Capital LLP
LSP Life Sciences Partners (Netherlands)
Mann Bioinvest Limited
Medicxi Ventures
Mercia Technologies
Midven
Mitsui & Co. Global Investment, Inc. (Japan)
MS Ventures (Netherlands)
MVM Life Science Partners LLP
NBGI Private Equity Limited
NeoMed (Switzerland)
NetScientific
New Wave Ventures
Norgine Ventures
Novartis Venture Fund (Switzerland)
Novo A/S (Denmark)
Numis Securities
O2h Ventures Limited
Oberland Capital (Sweden)
Omnes Capital (France)
ORAVision Ventures (United States)
Oxford Sciences Innovation
Oxford Technology
Panakès Partners (Italy)
PDL BioPharma, Inc. (United States)
Perceptive Bioscience Investment
Pierre Fabre Fund for Innovation (France)
Polar Capital Partners
Private Investor
Rainbow Seed Fund
Remiges Ventures (United States)
Rosetta Capital Ltd
Roundcape Ltd
Samsung Ventures Santen, Inc. (United States)
SEP (Scottish Equity Partners)
Seroba Life Sciences (Ireland)
Seventure Partners (France)
Shikubeisho Partners (France)
Silicon Valley Bank
Sofinnova Partners (France)
Spark Impact
SR One
Sunstone Capital (Denmark)
SV Life Sciences
Syncona Partners
SyndicateRoom
Takeda Ventures, Inc. (United States)
Tawhai Ltd
The Fulford Group
Torreya Partners
TVM Life Science Management (Germany)
UCL Business PLC
Ventac Partners (Spain)
Visium Asset Management
Warwick Ventures Ltd
Wellington Partners (Germany)
WG Partners LLP
Woodford Investment Management
Wren Capital
Yorkville Advisors Global (United States)
Ysios Capital (Spain)

Global pharma and medtech 2016

BioTrinity 2016 global pharma and medtech attendance included sixty BD&L executives as well as corporate venture funds representing most of the major players in the sector. This included many Europe-wide leads, and a growing number of global leads. Recent years have seen more senior business development involvement with more key players being represented from both their BD&L and corporate venture sides, as well as dual-role early-stage investment/licensing leads.

A. Menarini I.F.R. - Senior Licensing Manager (Italy)
AbbVie - Senior Director and Head of Academics, Search and Evaluation (United States)
Abbvie - Executive Vice President & Chief Strategy Officer (United States)
AbbVie - Director, Search & Evaluation Europe (Germany)
AbbVie - VP, Development (United States)
AbbVie - Sr. Director, Search and Evaluation Immunology (United States)
AbbVie - VP, Licensing & Acquisitions (United States)
AbbVie - Vice President, Search and Evaluation (United States)
AbbVie - Director, Venture and Early Stage Collaboration (USA)
AbbVie - Senior Director, Head Search and Evaluation Oncology (United States)
Amgen - Exec Director of Corporate Development (Switzerland)
Amgen - Executive Director, Corporate Development
AstraZeneca - Business Development and Partnering Communications Director
AstraZeneca - Head, Oncology Search & Evaluation
Bayer Pharma AG - Director Early Licensing (Germany)
Boehringer Ingelheim GmbH - Vice President
Boehringer Ingelheim Venture Fund (Germany)
Boehringer Ingelheim GmbH - Investment Manager (Germany)
Bristol-Myers Squibb - Director, Business Development (United States)
Bristol-Myers Squibb - YourEncore Consultant (United States)
Bristol-Myers Squibb - Vice President, Business Development (United States)
Bristol-Myers Squibb - Business Development Operations Lead (United States)
Bristol-Myers Squibb - Director, Search & Evaluation, Oncology (United States)
Bristol-Myers Squibb - Director, Technology Transactions (United States)
Bristol-Myers Squibb - SVP Drug Discovery Research (United States)
Bristol-Myers Squibb - SVP, R&D Operations (United States) Bristol-Myers Squibb - Head of EMAC Medical (United States)
Bristol-Myers Squibb - Director, Search & Evaluation, Specialty (United States)
Bristol-Myers Squibb - VP, Search & Evaluation, Business Development (United States)
BTG plc - Head of Strategy
BTG plc - SVP and Head of BD
Ipsen Bioinnovation Ltd - VP Neurology and Site Head
Ipsen Biopharm Limited - Senior Director Ipsen Pharma - Senior Director Corporate Business Development Oncology (France)
J&J Innovation London - Head of Johnson & Johnson Innovation London
Johnson & Johnson - Senior Director - Medicinal Chemistry Lead
Lilly - ‎Director External Innovation, Global External R & D
Lilly - Senior Director, Search & Evaluation Merck - Head of Business Development (France)
Mitsubishi Tanabe Pharma - Business Development
Mitsubishi Tanabe Pharma Corporation - Business Development (Japan)
Mitsubishi Tanabe Pharma Europe - General Manager MSD - Executive Director Oncology BD&L
MSD - Senior Vice President of Business Development and Learning
Pfizer - Senior Director, UK Scouting and Innovative Medicines Initiative
Pierre Fabre - External Innovation UK / Northern Europe (France)
Pierre Fabre Medicament - Business Development Manager (France)
Pierre Fabre Medicament - Senior Innovation Manager (France)
Sanofi - AVP & Principle Sunrise (United States)
Sanofi - Head of Europe, External Science and Partnering (France)
Sanofi - VP Head R&D Alliance Management and Transaction
Sanofi - Manager, External Science & Partnering, UK
Sanofi - Global Head, External Innovation Drug Discovery Platform (Germany)
Sanofi - Head of External Science and Partnering UK and Ireland
Santen, Inc. - Director & Head, US BD & Venture Management (United States)
Santen, Inc. - Venture Management (United States)
Takeda Pharmaceutical Company Limited - Director, Business Development
Takeda Pharmaceuticals International, Inc. - Vice President, Search & Evaluation (United States)
Teva Pharmaceutical Industries, Ltd. - Head of European Business Development (Netherlands)
UCB Biopharma sprl - Head of Global Business Development (Belgium)
UCB Biopharma sprl - Director Global Business Development

Exhibitors 2016

A J Gallagher
Advantage Austria
Air Products plc
Cobra Biologics
Confluence Tax LLP
DanMedical Ltd
Discovery Park
Dora Wirth (Languages) Ltd.
Enterprise Europe Network
Fisher Scientific
Flanders Investment and Trade
Hammersmith Medicines Research
Hays Life Science
HistologiX
Honeywell
Illingworth Research
Innovate UK
J A Kemp
Life Sciences Hub Wales
Management Learning & Coaching Ltd (ML&C)
Manentia Ltd
Mathys & Squire LLP
MedCity
MEPC Ltd
NIHR Clinical Research Network
Northern Powerhouse
Nova Language Services Ltd.
Oxford Academic Health Science Network (AHSN)
Oxford Science Park
Oxford University Hospitals NHS Trust and the University of Oxford
Panacea Innovation
Penningtons Manches LLP
Pharmaterials Ltd
Re-Pharm
Richmond Pharmacology Ltd
SCI
SynbiCITE
SyndicateRoom
Syne qua non
Tharsus
The BioHub Birmingham
Tissue Solutions Ltd
Wessex Academic Health Science Network
World Courier UK Ltd

Showcases 2016

Later Stage Biotech
  • Acrux
  • Cell Medica
  • Eli Lilly
  • Mereo Biopharma
  • Neovacs
  • Oncotherics
  • Sanofi
  • Shin Poong Pharma
  • UCB
  • Virttu Biologics
  • Wickham Laboratories
  • Zealand Pharma

Later Stage Medtech

  • Acarix
  • Momentum Bioscience
  • Nexstim
  • OBS Medical

Biotech Therapeutics

  • Amal Therapeutics
  • Apeptico
  • APIM Therapeutics
  • Cellestia Biotech
  • Cypralis
  • Elasmogen
  • e-Therapeutics
  • Eudendron
  • GENEAMED
  • Hercules Pharma
  • Karus Therapeutics
  • NeRRe Therapeutics Ltd
  • Neuro-Bio
  • Oryzon Genomics
  • PCI Biotech
  • Peptinnovate
  • Phision Therapeutics
  • PIQUR Therapeutics
  • PRAGMA Therapeutics
  • PsiOxus Therapeutics
  • Sareum
  • Thromboserin Limited
  • Tusk Therapeutics

Biotech Platform Technology

  • Abzena
  • Antikor BioPharma
  • Aurealis Pharma
  • CN Bioinnovation
  • Destiny Pharma
  • DJS Antibodies
  • GeneFirst
  • Glide Technologies
  • Healx
  • Ligand
  • N4 Pharma
  • Nanobiotix
  • Nanomerics
  • NPSC (National Phenotypic Screening Centre)
  • OncoQr ML
  • Orbit Discoveries
  • Orla Protein Technologies
  • Physiomics
  • Somanautix
  • Synpromics
  • TRIANNI

Medtech

  • Alesi Surgical
  • BeamLine Diagnostics
  • BioMarker Strategies
  • Capillary Film Technology
  • Edinburgh Molecular Imaging
  • GREENBONE ORTHO SRL
  • i3a Technologies
  • ICT Health
  • MedX Health
  • NALIA Systems Limited
  • NIMGenetics
  • Photo Dynamic Therapy
  • ProAxsis Ltd

Biotech Advanced Therapeutics

  • Alfacyte
  • apceth
  • Curileum Discovery
  • Immatics Biotechnologies
  • MiNA Therapeutics
  • OrthoSera
  • PolTREG
  • Ryboquin Company

Contract Research

  • Centre for Process Innovation
  • INOVOTION
  • J&P Medical Research
  • KWS BioTest
  • PRECLIN Biosystems
  • Sygnature Discovery

Keynotes and Panels 2016

A) Keynotes 2016

A manifesto for health and life sciences in the UK

Rt. Hon. George Freeman, Minister for Life Sciences, UK Government

 

Fast forward: vision for biotech 2030

Jim Mellon, Serial entrepreneur and founder, Mann Bioinvest

 

Innovation with impact

Professor Stephen Caddick, Director of Innovation, Wellcome Trust

 

Dementia discovery fund: a new collaborative approach to major unmet medical needs

Dr Tetsuyuki Maruyama, Chief Scientific Officer, Dementia Discovery Fund

B) Panel Discussions 2016

1) Building long-term value without an exit in mind

Chaired by:

Tim Haines, Managing Partner, Abingworth

Panellists:

Tim Bird, Partner, Corporate, Fieldfisher

Kevin Bottomley, Partner, Results Healthcare

Ed Hodgkin, Partner, Syncona Partners

Nigel Pitchford, CIO, Imperial Innovations

Saku Saha, Fund Manager, Woodford Investment Management

Miguel Stevens, VP, Head of Global Business Development, UCB BioPharma

 

2) Trends in innovative medtech investment every CEO should know

Chaired by:

Alan O’Connell, Partner, Seroba Life Sciences

Panellists:

Daniel Bach, Healthcare Ventures, Imperial Innovations

Alessio Beverina, General Partner, Panakès Partners

Jason Lettmann, Partner, Lightstone Ventures & Morgenthaler Ventures

Bruno Montanari, Partner, Omnes Capital

Ena Prosser, Partner, Fountain Healthcare Partners

Rainer Strohmenger, General Partner, Wellington Partners

 

3) How will immuno-oncology deliver on its promise?

Chaired by:

John Carroll, Editor-in-Chief, FierceBiotech

Panellists:

Carl Decicco, SVP Drug Discovery Research, Bristol Myers-Squibb

Luc Dochez, CEO, Tusk Therapeutics

Iain Dukes, SVP Business Development & Licensing, MSD

Niels Emmerich, Senior Director, Global Head Search & Evaluation Oncology, AbbVie

Hyam Levitsky, Executive Vice President, Chief Scientific Officer, Juno Therapeutics

 

4) Precision medicine: how to collaborate on big data to generate value In drug development

Chaired by:

Alison Dennis, Partner, Head of Life Sciences and Healthcare Group, Fieldfisher

Panellists:

Richard Barker, Chairman, Precision Medicine Catapult

Mark Beggs, CEO, Stratified Medicine Scotland

Mark Caulfield, Chief Scientist, Genomics England

John Colenutt, CEO, Genomics plc

Nick La Thangue, CEO, Oxford Cancer Biomarkers

Tero Silvola, CEO, BC Platforms AG

 

 5) EY’S “Beyond Borders” Report

Ian Oliver, Executive Director, EY

EY’s annual observations on the financial performance, financing and M&A/collaboration trends of the Global, European and UK Biotechnology Industry for 2015.

 

6) EY’S “Pulse of the Industry” Report

 Adrian Nicholls, Valuation & Business Modelling Service Line Leader, EY

EY’s annual observations on the financial performance, financing and M&A/ collaboration trends of the Medical Device Industry for 2015.

 

7) Can European capital take biotechs all the way?

Chaired by:

Antoine Papiernik, Managing Partner, Sofinnova Partners

Panellists:

Alex Pasteur, Partner, F-Prime Capital Partners

David Phillips, Partner, SR One

Clare Terlouw, Managing Director, Corporate Broking and Advisory, Numis Securities

Sander van Deventer, General Partner, Forbion Capital

 

8) How patient groups believe technology will impact their experience by 2030

Chaired by:

Tina Tan, Editor, Clinica Medtech Intelligence

Panellists:

Sophie Baratte, CEO, Cellnovo Group SA

Keith Errey, CEO, Isansys Lifecare

Matthew Goodman, CMO, Mapmyhealth

Ralph Holme, Head of Biomedical Research, Action on Hearing Loss

Arthur Roach, Director of Research, Parkinson’s UK

Michael Seres, Founder, 11Health and Technologies

 

 

9) Is the UK becoming the European powerhouse for biotech?

Chaired by:

Andrew Ward, Pharmaceuticals Correspondent, Financial Times

Panellists:

John Jeans, Advisor to the Prime Minister, Office of Life Sciences

Henk Joos, CEO, FlandersBIO

Dr Virginia Acha, Executive Director of Research, Medical & Innovation, ABPI

Chris Doherty, Site Director, Alderley Park, Manchester Science Partnerships

Zahid Latif, Head of Healthcare, InnovateUK

Tim Luker, Director External Innovation, Global External R & D, Eli Lilly

 

 

10) Crystallizing value without the equity markets

Chaired by:

Stephanie Léouzon, Partner and Head of Torreya Partners Europe

Panellists:

Ray Barlow, Executive Director, Corporate Development, Amgen

Margarita Chavez, Director, Ventures & Early Stage Collaborations, AbbVie

Genghis Lloyd-Harris, Partner, Abingworth

Daniel Mahony, Fund Manager - Healthcare, Polar Capital

Richard Mason, Head of Johnson & Johnson Innovation, Johnson & Johnson Innovation

Graziano Seghezzi, Partner, Sofinnova Partners

 

11) Debate: how sustainable is the biotech boom?

Co-chaired by:

Sam Fazeli, Head of European Research, Pharmaceuticals Analyst, Bloomberg Intelligence

Mike Ward, Chief Content Officer, Datamonitor Healthcare & SCRIP Intelligence

Panellists:

Kate Bingham, Managing Partner, SV Life Sciences

Reza Halse, Head of MSD European Innovation Hub; Partner, MRL Ventures

Debbie Harland, Partner, SR One

Kevin Johnson, Partner, Medicxi Ventures

Terence Porter, VP, Search & Evaluation, Takeda

David U’Prichard, Chairman of the Advisory Board, BioMotiv

 

12) Europe’s most notable transactions: deal-making insight from the trenches

Chaired by:

Jenny Laird, Senior Director, Search & Evaluation, Eli Lilly

Data provider:

Fintan Walton, CEO, PharmaVentures

Panellists:

Frank Grams, VP, Head Alliance Management & Transactions, Sanofi R&D, Sanofi

Scott Cuthill, Senior Director, Ipsen Biopharm

Gilles Nobecourt, Partner, Edmond de Rothschild Investment Partners

Edward van Wezel, Managing Partner, Biogeneration Ventures

Malcolm Weir, CEO, Heptares

Workshops 2016

1) Harnessing the power of a national network to deliver your clinical trials

Hosted by: The NIHR Clinical Research Network

With speaker: Matt Cooper, Director, NIHR Clinical Research Network

 

2) The road through to pre-IPO and NASDAQ

Hosted by: Chris Farmakis, EC Fund Manager, GLE Group, Enterprise Europe Network

With speakers: Asaf Homossany, Managing Director EMEA, NASDAQ

 

3) Patients before protocols, patient centric clinical trials

Hosted by: David Spillett, Key Account Director, World Courier

 

4) Open innovation and the translation of university research into new companies

Hosted by: Nick Scott-Ram Director of Commercial Development, Oxford Academic Health Science Network

With speakers: Prof. Chas Bountra, CSO, Structural Genomics Consortium, University of Oxford

Ian Bingham, Senior Partner, IP Asset

Dr. Wen Hwa Lee, Programme Director, Disease Foundations Network, Structural Genomics Consortium, University of Oxford

Dr. Nicholas Edwards, Wealth Creation, Oxford Academic Health Science Network

 

5) The other side of the innovation ledger: changes in early-stage sourcing and deal-making

Hosted by: Virginia Acha Executive Director - Research, Medical and Innovation, The Association of the British Pharmaceutical Industry

Chair: Jon Rees, Managing Director, Jon Rees Associates

With speakers: Peter Hamley, Global Head, External Innovation and Sourcing, LGCR, Sanofi

Matt Foy, Partner, SR One

Kevin Johnson, Partner, Medicxi Ventures

Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson Innovation London

Andrew Clempson, Research Policy Manager, AMRC

  

6) Introducing engineering biology: creating high value products & processes

Hosted by: Dr Stephen Chambers, CEO, SynbiCITE and

Dr John Collins, Commercial Director, SynbiCITE

 

7) Genome editing technology - the ethical and regulatory viewpoint

Hosted by: Sarah Ellson, Partner, Fieldfisher, Alison Dennis, Partner, Fieldfisher

With speakers:
Dr. Beatriz San Martin, Partner, Fieldfisher

Prof Dave Archard, Prof. School of Politics, International Studies and Philosophy, Queen’s University Belfast

Sarah Rappaport, Policy Officer, Wellcome Trust

Dr. Rafael J. Yáñez-Muñoz, Reader in Advanced Therapy, University of London

 

 8) At what point does developing your people become critical to your success?

Hosted by: Jacky Ling, Commercial Manager, Management Learning & Coaching

With speakers:

Mike Mair, Head of Training and Organisational Development, Bard Pharmaceuticals

Diana Barden, Director Management Training Coaching, Management Learning & Coaching

 

9) Locating in the UK - how UKTI can assist

Hosted by: Jon Mowles, Sector Specialist, Life Sciences, UKTI

Speaker: Julian Christmas, Tax and Finance Policy Specialist, UKTI

 

10) Regulatory Acceleration for Innovation in the UK - What’s next?

Hosted by: Ian Hudson, CEO, Medicines & Healthcare products Regulatory Agency (MHRA)

With speakers:

Stuart Dollow, Founder, Vermilion Life Sciences

Pete Embley, Senior Director, Regulatory Sciences, RRG, a VCLS Company

 

11) Together, accelerating drug development to beat cancer sooner: Innovative research partnerships with the Cancer Research UK Centre for Drug Development

Hosted by: Juliana Callaghan, New Projects Manager and Communications and Marketing Lead, Cancer Research UK Centre for Drug Development

With speakers:

Dr. James Ritchie, Drug Development Scientist, Translational Sciences, Cancer Research UK Centre for Drug Development

Dr. George Tzircotis, Senior Licensing Manager, Clinical Partnerships Team, Cancer Research UK Centre for Drug Development